Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics, Inc. has filed a shelf registration statement that allows it to offer up to $750,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. The filing also carries forward $326,585,963 of previously registered but unsold securities from an expiring shelf under SEC Rule 415(a)(6), so those amounts remain available without interruption. Proceeds from future offerings may be used for general corporate purposes, including clinical trials, research and development, and general and administrative expenses. Avalo is a clinical-stage biotechnology company focused on IL‑1β-based therapies, led by AVTX‑009 in a Phase 2 trial for hidradenitis suppurativa, with topline data expected in the second quarter of 2026.
Avalo Therapeutics, Inc. reported an insider Form 4 transaction by its Chief Medical Officer. On December 10, 2025, the officer disposed of 1,013 shares of Avalo Therapeutics common stock at $4.1 per share. After this transaction, the officer beneficially owns 3,622 shares, which include shares acquired pursuant to Avalo Therapeutics' Employee Stock Purchase Plan as part of this reporting transaction.
Avalo Therapeutics’ chief strategy officer reported a small change in personal share holdings. On 12/10/2025, the officer disposed of 637 shares of Avalo Therapeutics common stock at a price of $4.1 per share, according to an SEC insider ownership report.
After this transaction, the officer directly beneficially owns 2,655 shares of Avalo Therapeutics. These 2,655 shares are described as having been acquired under the company’s Employee Stock Purchase Plan as part of the reported activity, indicating ongoing participation in the company’s equity programs.
Avalo Therapeutics, Inc. reported an equity transaction by its Chief Legal Officer on December 10, 2025. The officer reported a transaction in Avalo common stock coded “F” involving 1,016 shares at a price of $4.10 per share. After this transaction, the officer beneficially owns 3,634 shares of Avalo common stock. A note explains that these 3,634 shares were acquired under Avalo’s Employee Stock Purchase Plan as part of the reported transaction.
Avalo Therapeutics, Inc. chief financial officer Christopher Sullivan reported a change in his ownership of Avalo common stock. On 12/10/2025, 155 shares of common stock were disposed of at $4.1 per share, leaving him with beneficial ownership of 17,338 shares.
The beneficially owned amount includes 417 additional shares acquired pursuant to Avalo Therapeutics, Inc.'s Employee Stock Purchase Plan as a part of this reporting transaction. The report is a Form 4 filed by one reporting person in his capacity as an officer (chief financial officer).
Avalo Therapeutics, Inc. (AVTX) reported insider activity by one of its directors involving common stock and stock options on November 14, 2025. The director exercised a stock option to acquire 8,200 shares of common stock at an exercise price of $9.88 per share and then sold those 8,200 shares at a weighted average price of $14.3474 per share. On the same date, the director also sold an additional 3,167 shares of common stock at $14.30 per share, for total reported sales of 11,367 shares. Following these transactions, the director reported owning 0 shares of common stock directly and 16,400 stock options with an exercise price of $9.88 per share, expiring on August 13, 2034, which vest in three equal annual installments on March 28, 2025, 2026 and 2027.
Avalo Therapeutics (AVTX) filed a Form S-8 registering 1,300,000 shares of common stock for issuance under the Avalo Therapeutics, Inc. 2025 Inducement Award Plan. These shares may be issued and sold pursuant to awards granted under the plan.
The company identifies as a non-accelerated filer and a smaller reporting company. Standard indemnification and insurance provisions for directors and officers are described, and customary undertakings and incorporated reports are included.
Avalo Therapeutics (AVTX) reported Q3 2025 results with a net loss of $30.6 million (basic EPS $2.19 loss). The quarter showed no revenue, while operating expenses were $19.2 million, led by research and development at $13.6 million and general and administrative at $5.6 million. Other expense reflected a $12.5 million non-cash loss from the change in fair value of the derivative liability.
As of September 30, 2025, cash and cash equivalents plus short-term investments totaled $111.6 million. Year to date, operating cash outflow was $37.2 million, with additional net investing outflows of $84.1 million and financing inflows of $13.9 million. Management states existing cash and investments are expected to fund operations for at least twelve months from the filing date.
The derivative liability was $23.2 million at quarter-end, up from $8.5 million at year-end 2024. During Q3, the company raised $14.4 million net via its at-the-market program, issuing 1.7 million shares. Common shares outstanding were 17,827,635 as of September 30, 2025, and 18,133,968 as of November 3, 2025.
Avalo Therapeutics (AVTX) reported it issued a press release announcing financial results for the quarter ended September 30, 2025. The company furnished the release as Exhibit 99.1 under Item 2.02, stating it is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically referenced.
The filing lists common stock trading on the Nasdaq Capital Market under AVTX and includes Inline XBRL cover pages as Exhibit 104.
Avalo Therapeutics reported a clinical milestone: it has completed enrollment in its Phase 2 LOTUS Trial evaluating AVTX-009 for hidradenitis suppurativa. The company disclosed the update via a press release furnished as Exhibit 99.1 to this report, dated October 29, 2025. This marks the transition from recruitment to data collection and analysis for the study.